HBV cccDNA fluorescent quantitative PCR detection kit and application thereof

The gaps in rcDNA were removed by digestion of Exo I enzyme and Exo III enzyme, combined with primers and fluorescent probes designed across the gaps, solving the specificity and low sensitivity of HBV cccDNA detection, and achieving efficient real-time quantitative PCR detection, suitable for Clinical application.

CN118932115APending Publication Date: 2024-11-12JIANGSU JIUCHUAN BIOTECHNOLOGY CO LTD
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202411121332.5
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-15
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

The existing HBV cccDNA detection methods have problems with low specificity and sensitivity, and are difficult to widely use in clinical applications, especially due to the problems of rcDNA amplification interference and complicated operation and high cost.

Method used

Exo I enzyme and Exo III enzyme were used to digest and remove the gap-with hepatitis B rcDNA, and design PCR primers and fluorescent probes across the gap to improve the specificity and sensitivity of cccDNA detection.

Benefits of technology

It significantly improves the specificity and sensitivity of HBV cccDNA detection, reduces the amplification interference of non-cccDNA, and realizes efficient detection of real-time fluorescence quantitative PCR, which is suitable for clinical auxiliary diagnosis and anti-hepatitis B virus drug development.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118932115A_ABST
    Figure CN118932115A_ABST
Patent Text Reader

Abstract

The invention belongs to the technical field of nucleic acid detection, and particularly relates to a fluorescent quantitative PCR (polymerase chain reaction) detection kit for hepatitis B virus covalent closed circular deoxyribonucleic acid (HBV cccDNA) and application of the fluorescent quantitative PCR detection kit. The HBV cccDNA fluorescent quantitative PCR detection kit comprises a primer HBV-S, a primer HBV-AS, a fluorescent probe HBV-P, a Taq enzyme, an exonuclease I and an exonuclease III, and the sequences of the primer HBV-S, the primer HBV-AS and the fluorescent probe HBV-P are respectively as shown in SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4. According to the kit provided by the invention, the ExoI enzyme and the ExoIII enzyme are adopted to perform enzyme digestion treatment on the sample DNA, and the ExoI enzyme and the ExoIII enzyme can digest non-cccDNA, so that the specificity and the sensitivity of detection are greatly improved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of nucleic acid detection, and in particular relates to a hepatitis B virus covalently closed circular deoxyribonucleic acid (HBV cccDNA) fluorescent quantitative PCR detection kit and an application thereof. Background Art

[0002] An estimated 350 million people worldwide have been infected with hepatitis B virus, with more than 80 million people in my country infected with the virus, and the number is growing at a rate of 1 million new infections each year. Hepatitis B treatment requires patients to take medication for a long time, which not only puts a great burden on their bodies, but also increases economic pressure. Moreover, many people will eventually develop serious liver diseases, including cirrhosis and hepatocellular carcinoma (HCC). The goal of chronic hepatitis B treatment is to control the virus at the lowest level, thereby controlling the development of liver disease. However, the high recurrence rate of chronic hepatitis B treatment after treatment termination has always been puzzling.

[0003] Hepatitis B virus (HBV) belongs to the hepadnavirus family. Its genome is double-stranded relaxed circular DNA (rcDNA) with a relative molecular mass of (116-210)×10 9 , with a total length of approximately 3.2kb. In the life cycle of HBV, the formation of covalently closed circular DNA (cccDNA) is a key step. It is the original replication template of HBV and the most important molecular marker for persistent viral infection. It is of great significance for the replication and establishment of the infection state of HBV. Understanding the role of cccDNA in the pathogenesis of chronic hepatitis B may discover new antiviral drug targets and promote the design of antiviral strategies to reduce and ultimately remove the cccDNA pool. However, this viral marker has not yet been widely used in clinical practice. Therefore, it is necessary to develop reliable cccDNA measurement methods when evaluating anti-HBV efficacy and treatment endpoints. Recently, several methods for detecting HBV cccDNA have been developed, such as PCR amplification and Southern blotting, which are reproducible. However, these methods can only be used in very small clinical laboratories, and Southern blotting is very time-consuming and complicated. In addition, some studies have reported polymerase chain reaction (HBV) detection methods for HBV cccDNA. However, most of these reported assays lack specificity or sensitivity and cannot be put into practical application.

[0004] For example, a Chinese patent application with publication number CN 108441578A discloses a digital droplet PCR detection method and kit for hepatitis B virus cccDNA, which uses a special tissue DNA extraction kit to extract HBV DNA, and uses selective fluorescent quantitative PCR technology to detect hepatitis B virus cccDNA. After nucleic acid extraction, PSAD enzyme treatment and digital droplet PCR method are used to amplify the target gene and directly quantify it to improve the detection sensitivity and specificity. However, the digital droplet PCR method is not only cumbersome and costly, but the PSAD enzyme cannot eliminate the interference of rcDNA amplification, making the specificity and sensitivity of cccDNA detection low, so this method is difficult to put into practical application. Summary of the invention

[0005] In view of the shortcomings of the prior art, the purpose of the present invention is to provide a HBV cccDNA fluorescent quantitative PCR detection kit and its application. The present invention uses Exo I enzyme and Exo III enzyme to digest and remove the nicked hepatitis B rcDNA, greatly reducing the amplification interference of non-cccDNA and improving the specificity and sensitivity of cccDNA detection.

[0006] To achieve this object, the present invention adopts the following technical solutions:

[0007] A HBV cccDNA fluorescent quantitative PCR detection kit comprises a primer HBV-S, a primer HBV-AS, a fluorescent probe HBV-P, a Taq enzyme, an exonuclease I and an exonuclease III, wherein the sequences of the primer HBV-S, the primer HBV-AS and the fluorescent probe HBV-P are shown in SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4, respectively.

[0008] Since the extracellular HBV DNA of HBV patients is a relaxed circular double-stranded DNA (rcDNA) molecule, both chains are not closed, the negative chain is longer, contains the full-length gene of the HBV genome, and has a "nick" of several bases between its 5' start end and 3' end; the positive chain is shorter, has a larger "gap", and its 3' end is not fixed, so the length is variable, about 50% to 100% of the length of the negative chain. Utilizing the characteristic of HBV having a gap, the present invention designs a PCR primer across the gap to detect cccDNA according to its principle.

[0009] The exonuclease I (Exo I enzyme) in the kit of the present invention has the exonuclease activity of degrading single-stranded DNA from the 3'-5' direction, and can gradually release the 5'monophosphate of deoxyribonucleic acid, and leave the complete 5'end dinucleotide; at the same time, the exonuclease III (Exonuclease III, Exo III enzyme) acts on double-stranded DNA, and gradually catalyzes the removal of mononucleotides along the 3'→5' direction; Exonuclease III can act on the nicking of double-stranded DNA to produce single-stranded gaps, and the best substrate of the enzyme is the double-stranded DNA molecule exonuclease I (Exo I enzyme) with a flat end and a 5' protruding end, but it can also act on the nick of double-stranded DNA, degrade DNA molecules from 3', and release 5'mononucleotides. Therefore, the present invention uses Exo I enzyme and Exo III enzyme to digest and remove the hepatitis B rcDNA with a gap, greatly reducing the interference of amplification of non-cccDNA, and improving the specificity and sensitivity of detecting cccDNA.

[0010] Furthermore, the concentration of the exonuclease I is 10U, and the concentration of the exonuclease III is 30U.

[0011] Furthermore, the HBV cccDNA fluorescent quantitative PCR detection kit also includes a hepatitis B virus cccDNA positive control, a negative control and a PCR buffer solution.

[0012] Moreover, the present invention also provides the use of the HBV cccDNA fluorescent quantitative PCR detection kit as described above in the preparation of HBV cccDNA detection reagents.

[0013] Furthermore, according to the complete sequence of HBV, primers were designed across the gap in the conserved region of the gene. In the pre-C coding region of the HBV genome, primers HBV-S, primers HBV-AS and fluorescent probe HBV-P with the following sequences were designed and synthesized; wherein:

[0014] Primer HBV-S: 5′-GTCTCCCCGTCTGTGCCTT-3′ (nt1544-nt1563);

[0015] Primer HBV-AS: 5′-GCCCCAAAGCCACCCAG-3′ (nt1903-nt1886);

[0016] Fluorescent probe HBV-P: 5'-FAM-ATCTGCCGGACCGTGTG-HQ1-3'(nt1567-nt1581).

[0017] Further, after the sample HBV DNA is extracted, it is digested with a specific concentration of Exo I enzyme and Exo III enzyme to digest non-cccDNA. The operation method in some preferred embodiments is: 4 μL of 10-fold PCR buffer (Buffer), 0.2mmol / L dNTPs, 2.5mmol / L MgCl2, 0.2μmol / L of primer HBV-S and primer HBV-AS, 0.1μmol / L probe HBV-P, 1U of DNA polymerase, 5μL of extracted hepatitis B DNA template solution, 0.5μL of Exo I enzyme (10U) and Exo III enzyme (30U), and the insufficient part is supplemented with distilled water. Then the reaction system is placed in a 37°C environment for digestion for 2 hours, and then inactivated at 70°C for 30min.

[0018] Furthermore, the quantitative standard in the present invention is a 3.2kb plasmid of the full gene of hepatitis B virus; the negative control is Dane particles (large spherical particles of hepatitis B virus) of hepatitis B virus serum without cccDNA; and the positive control is a 3.2kb full-length plasmid of hepatitis B virus at medium and low concentrations.

[0019] Further, in some preferred embodiments, the preparation method of the negative control of the HBV cccDNA kit is as follows: first, filter the prepared 10mL HBV serum with a 0.45um filter membrane; filter the 35% sucrose solution with a 0.25um filter membrane; add the filtered 35% sucrose solution to a 50mL ultracentrifuge tube, and then slowly spread the filtered serum on the sucrose surface (the volume ratio of sucrose to serum is 1:2.5); then use a high-speed centrifuge to ultracentrifuge at 25'000rpm and 4°C for 18 hours; after the centrifugation, take out the ultracentrifuge tube, discard the supernatant and invert the ultracentrifuge tube on a clean absorbent paper, and place it at room temperature for 3-5 minutes; add 500ul PBS to the ultracentrifuge tube and dissolve it at 4°C overnight; finally, collect the suspension as the negative control of the HBV cccDNA kit.

[0020] Further, in some preferred embodiments, the preparation method of HBV cccDNA standard is: HBV DNA is isolated from the serum of chronic hepatitis B patients who have not been treated with antiviral drugs, and then the HBV full gene plasmid pUC-536209 (genotype C) is constructed. Take 5ug (200ng / μL, 25μL) of pUC-536209 plasmid and perform enzyme digestion reaction according to the following system: EcoR I endonuclease 2μL (50U), 10×Buffer 4μL, plasmid 25μL (200ng / μL), ddH2O9μL, total volume 40μL, centrifuge evenly, in a 37°C water bath for 2 hours, and then use Shanghai Biotech Gel Recovery Kit to recover 3.2kbDNA fragments. The 3.2kb linear HBV DNA fragment was connected in the following system: T4 ligase 20μL (10000u), 10×T4 Buffer 200μL, 3.2Kb linear DNA 25μL, ddH2O 1300μL, total volume 1000μL, centrifuge to mix, connect overnight at 16°C for 12-24 hours, take out the connection product, divide it into two tubes, 500μL in each tube, add saturated phenol and chloroform 400μL each to each tube, mix it upside down, let it stand for 20 minutes, centrifuge at 12500rpm / min for 15 minutes, and obvious stratification can be seen. The supernatant was aspirated with a pipette and added to a new 1.5mL Ep tube, about 500μL in each tube, 50μL NaAc, 1000μL anhydrous ethanol, 5μL glycogen were added, and the DNA was precipitated overnight at -20°C. The product was taken out, centrifuged at 12500rpm / min for 15 minutes, the supernatant was discarded, and 1000μL of 70% ethanol solution was added, and the supernatant was centrifuged at 12500rpm / min for 8 minutes, the supernatant was discarded, the lid was opened and dried for 3-5 minutes, and then 50μL ddH2O was added to dissolve the DNA. Prepare 1% agarose gel, operate as before, add the saturated phenol-chloroform extracted connection product DNA to the sample well, electrophoresed at a voltage of 150V and a current of 60mA for 40 minutes, and then cut the gel to recover the DNA fragment, and operate as before. The DNA with a marker molecular weight of 2.1Kb is the HBV cccDNA standard. The HBV cccDNA standard is identified by sequencing.

[0021] Compared with the prior art, the present invention has the following beneficial effects:

[0022] The kit provided by the present invention can detect hepatitis B virus cccDNA in real time using a fluorescent probe. Compared with conventional PCR detection, the real-time fluorescent PCR detection method of the present invention improves the sensitivity and specificity of PCR detection, and is an ideal solution for detecting HBV cccDNA. The present invention uses a special tissue DNA extraction kit to extract HBV DNA. After the nucleic acid extraction of the hepatitis B sample is completed, the DNA sample is treated with Exo I enzyme and Exo III enzyme to eliminate the interference of non-cccDNA such as rcDNA; at the same time, based on the HBV sequence analysis, the present invention designs primers spanning two gaps so that rcDNA will not be amplified, while cccDNA can be selectively amplified, and finally significantly improves the specificity and sensitivity of detecting cccDNA. The present invention can not only be used for the research of hepatitis B virus and the development of anti-hepatitis B virus drugs, but also can be used as an auxiliary diagnosis method for HBV infection in clinical laboratories and a monitoring method for clinical treatment effects, and has potential application value and social value. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 3×10 of the HBV cccDNA standard prepared in Example 1 of the present invention 7 , 3×10 6 , 3×10 5 , 3×10 4 and 3×10 3 copies / mLPCR amplification results diagram;

[0024] Figure 2 3×10 of the HBV cccDNA standard prepared in Example 1 of the present invention 7 , 3×10 6 , 3×10 5 , 3×10 4 , 3×10 3 , 3×10 2 , 3×10 1 copies / mLPCR amplification results diagram;

[0025] Figure 3 This is the result of PCR amplification of clinical samples. DETAILED DESCRIPTION

[0026] The technical solution of the present invention is described in detail below in conjunction with specific embodiments and their accompanying drawings. The embodiments recorded herein are specific embodiments of the present invention, which are used to illustrate the concept of the present invention; these descriptions are explanatory and exemplary and should not be construed as limitations on the embodiments of the present invention and the scope of protection of the present invention. In addition to the embodiments recorded herein, those skilled in the art can also adopt other obvious technical solutions based on the contents disclosed in the claims of this application and its specification, including technical solutions that adopt any obvious replacements and modifications to the embodiments recorded herein.

[0027] Example 1

[0028] A method for detecting hepatitis B virus covalently closed circular deoxyribonucleic acid (HBV cccDNA) based on exonuclease I (Exo I enzyme) and exonuclease III (Exo III enzyme) treatment:

[0029] (1) The kit includes the following components: a pair of specific primers (primer HBV-S and primer HBV-AS), a specific fluorescent probe HBV-P, Taq enzyme, Exo I enzyme and Exo III enzyme, hepatitis B virus cccDNA positive control, negative control, hepatitis B virus cccDNA quantitative standard and PCR buffer.

[0030] (2) Preparation of primers and probes: Based on the complete HBV sequence, primer HBV-S, primer HBV-AS and fluorescent probe HBV-P with the following sequences were designed and synthesized in the pre-C coding region of the HBV genome; wherein:

[0031] Primer HBV-S: 5′-GTCTCCCCGTCTGTGCCTT-3′ (nt1544-nt1563);

[0032] Primer HBV-AS: 5′-GCCCCAAAGCCACCCAG-3′ (nt1903-nt1886);

[0033] Fluorescent probe HBV-P: 5'-FAM-ATCTGCCGGACCGTGTG-HQ1-3'(nt1567-nt1581).

[0034] (3) Preparation of reaction solution: Each reaction solution was 36 μL and contained the following components: 5×PCR Buffer, 0.2 mmol / L dNTPs, 2.5 mmol / L MgCl2, 0.2 μmol / L each of primer HBV-S and primer HBV-AS, 0.1 μmol / L probe HBV-P, and 1 U of DNA polymerase.

[0035] (4) Enzyme digestion: In a 40 μL total reaction system, add 3 μL of 10x buffer, 5 μL of extracted HBV DNA template solution, 0.5 μL each of Exo I enzyme (10U) and Exo III enzyme (30U), and use distilled water to supplement the insufficient amount. Place the reaction system in a 37°C environment for enzyme digestion for 2 hours, and then inactivate at 70°C for 30 minutes.

[0036] (5) Fluorescence quantitative detection: HBV cccDNA treated with Exo I and Exo III enzymes, with a concentration of 3×10 7 , 3×10 6 , 3×10 5 , 3×10 4 and 3×10 3 4 μL of each of the five standard samples with a concentration of 10 copies / mL was added to each of the five standard samples, and 36 μL of the reaction solution prepared in step (3) was added to each of the five standard samples and placed in separate reaction tubes for treatment. A blank tube and a negative control were also provided. Amplification was performed in each reaction tube, and the amplification result of the reaction tube containing the sample to be tested was compared with the amplification results of other reaction tubes to obtain the content of HBV cccDNA in the sample to be tested.

[0037] The amplification in step (5) is carried out in a Rohe480 fluorescence quantitative monitor: the temperature conditions during amplification are 50°C for 2 minutes, 94°C pre-denaturation for 5 minutes, 94°C for 10 seconds, and 60°C for 40 seconds, which constitute one cycle, for a total of 45 cycles.

[0038] (6) The preparation method of the negative control of the HBV cccDNA kit is as follows: first, filter the prepared 10 mL of HBV serum with a 0.45 um filter membrane; filter the 35% sucrose solution with a 0.25 um filter membrane; add the filtered 35% sucrose solution to a 50 mL ultracentrifuge tube, and then slowly spread the filtered serum on the surface of the sucrose (the volume ratio of sucrose to serum is 1:2.5); then high-speed centrifuge at 25'000 rpm and ultracentrifuge at 4°C for 18 hours; after centrifugation, remove the ultracentrifuge tube, discard the supernatant, and invert the ultracentrifuge tube on clean absorbent paper and leave it at room temperature for 3-5 minutes; add 500 ul of PBS to the ultracentrifuge tube and dissolve it at 4°C overnight; finally, collect the suspension for the negative control of the kit.

[0039] (7) The preparation method of HBV cccDNA standard is as follows: HBV DNA is isolated from the serum of chronic hepatitis B patients who have not been treated with antiviral drugs, and then the HBV full gene plasmid pUC-536209 (genotype C) is constructed. Take 5ug (200ng / μL, 25μL) of pUC-536209 plasmid and perform enzyme digestion reaction according to the following system: EcoR I endonuclease 2μL (50U), 10×Buffer 4μL, plasmid 25μL (200ng / μL), ddH2O9μL, total volume 40μL, centrifuge evenly, incubate in a 37℃ water bath for 2 hours, and then use Shanghai Biotech Gel Recovery Kit to recover the 3.2kbDNA fragment. The 3.2kb linear HBV DNA fragment was connected in the following system: T4 ligase 20μL (10000u), 10×T4 Buffer 200μL, 3.2Kb linear DNA 25μL, ddH2O1300μL, total volume 1000μL, centrifuge to mix, connect overnight at 16°C for 12-24 hours, take out the connection product, divide it into two tubes, 500μL in each tube, add saturated phenol and chloroform 400μL each to each tube, mix it upside down, let it stand for 20 minutes, centrifuge at 12500rpm / min for 15 minutes, and obvious stratification can be seen. The supernatant was aspirated with a pipette and added to a new 1.5mL Ep tube, about 500μL in each tube, 50μL NaAc, 1000μL anhydrous ethanol, 5μL glycogen, and DNA was precipitated overnight at -20°C. The product was taken out and centrifuged at 12500rpm / min for 15 minutes. After discarding the supernatant, 1000μL of 70% ethanol solution was added, and the mixture was centrifuged at 12500rpm / min for 8 minutes. The supernatant was discarded, and the mixture was opened and dried for 3-5 minutes, and then 50VL ddH2O was added to dissolve the DNA. Prepare 1% agarose gel and perform the same operation as before. The ligation product DNA extracted with saturated phenol-chloroform was added to the loading well. Electrophoresis was performed at a voltage of 150V and a current of 60mA for 40 minutes, and the gel was cut to recover the DNA fragments. The operation was the same as before. The DNA with a molecular weight marker of 2.1Kb is the HBV cccDNA standard. The HBVcccDNA standard product was identified by sequencing. The purified HBV cccDNA was accurately quantified using a nucleic acid protein UV analyzer, and a 10-fold serial dilution was performed to obtain concentrations of 3×10 7 , 3×10 6 , 3×10 5 , 3×10 4 , 3×10 3 , 3×10 2 and 3×10 1 The standard product with 1000 copies / mL was stored at -20℃ and has a validity period of one year. Among the above reagents, EcoR I endonuclease and T4 ligase were purchased from NEB, USA. The amplification results of cccDNA plasmid D are shown in the attached Figure 1-2 .

[0040] Example 2

[0041] Clinical sample validation:

[0042] The test kit prepared in Example 1 was used to test liver tissue samples and serum samples from 50 patients with hepatitis B virus (HBV), HBV cccDNA was detected in 50 liver tissue samples, accounting for 100% of the total.

[0043] Select 10 of the above samples 5 -10 8 IU / mL serum samples were collected from 10 patients and the test results showed that: 7 The following serum samples had no detectable cccDNA; 10 7 A small amount of cccDNA can be detected in the above samples; after using Exo I & III enzymes to digest the DNA samples, no cccDNA was detected in all serum samples, and the test results are shown in Table 1. This experiment shows that the cccDNA detection method of the present invention has high specificity, is basically not interfered by rcDNA, and can accurately and quantitatively analyze HBV cccDNA, which is far superior to general methods.

[0044] Table 1 Detection results of cccDNA in serum samples treated with Exo I & III enzymes

[0045]

[0046]

[0047] Among them, the concentration of HBV DNA in the DNA of 20 liver tissue samples was between 2.47E+06 and 1.89E+08; the concentration of cccDNA was greatly reduced after Exo I&III enzyme digestion, further proving the high specificity of the detection method. The results are shown in Table 2.

[0048] Table 2 Detection of total HBV DNA and cccDNA in liver tissue samples

[0049]

[0050] The detection sensitivity of this method is not less than 50 copies; the invention has the characteristics of good specificity, high sensitivity, accurate quantification, rapidity, simplicity and good repeatability. The invention uses Exo I enzyme and Exo III enzyme to pretreat hepatitis B virus DNA, and designs primers spanning two gaps so that rcDNA will not be amplified, while cccDNA can be selectively amplified (partial amplification results are shown in the attached Figure 3 ), thereby significantly improving the specificity and sensitivity of cccDNA detection.

[0051] The applicant declares that the above is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention shall fall within the protection scope and disclosure scope of the present invention.

Claims

1. A HBV cccDNA fluorescent quantitative PCR detection kit, characterized in that: It includes primer HBV-S, primer HBV-AS, fluorescent probe HBV-P, Taq enzyme, exonuclease I and exonuclease III, wherein the sequences of primer HBV-S, primer HBV-AS and fluorescent probe HBV-P are shown in SEQ ID NO: 2, SEQ ID NO: 3 and SEQ ID NO: 4 respectively.

2. The HBV cccDNA fluorescent quantitative PCR detection kit according to claim 1, characterized in that: The concentration of the exonuclease I is 10U, and the concentration of the exonuclease III is 30U.

3. The HBV cccDNA fluorescent quantitative PCR detection kit according to claim 1, characterized in that: Also included is a Hepatitis B virus cccDNA positive control, a negative control, and PCR buffer solution.

4. Use of the HBV cccDNA fluorescent quantitative PCR detection kit as described in any one of claims 1 to 3 in the preparation of HBV cccDNA detection reagents.

Citation Information

Patent Citations

  • Fluorescent quantitative PCR (Polymerase Chain Reaction) testing method for cccDNA (covalently closed circular deoxyribonucleic acid) of hepatitis B virus and kit thereof

    CN102329888A

  • Method for quantitatively detecting covalent closed circular DNA of hepatitis B virus by using digital PCR

    CN112662745A

  • Hepatitis B virus vector and application thereof

    CN114107377A